Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
ID: 349801Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349801

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html
Timeline
    Description

    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), has announced a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems." This initiative aims to foster collaborations between academic institutions and industrial partners to advance imaging technologies that address critical challenges in cancer detection, diagnosis, and treatment. The program is particularly focused on innovative solutions that enhance imaging capabilities tailored to the needs of end-users, thereby contributing to improved cancer research outcomes. Grants are available for projects lasting up to five years, with a maximum budget of $500,000 in direct costs per year, and applications are due by January 7, 2027. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-259-Full-Announcement.html
    PAR-23-259.html
    The National Institutes of Health (NIH), through its National Cancer Institute (NCI), has issued a Notice of Funding Opportunity (NOFO) titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems." This funding aims to foster collaborations between academic institutions and industrial entities to translate scientific advancements in imaging technologies to tackle cancer-related challenges. Notably, applications must feature strategic alliances that can identify and implement technological solutions for detection, diagnosis, and treatment of cancer. Eligible applicants include a broad array of organizations, such as higher education institutions, nonprofits, for-profits, and local, state, and tribal governments. Grants will cover projects up to five years, with budgets capped at $500,000 direct costs per year. Applications may involve optional clinical trials, but basic research or commercial production is not supported. Key dates include an open application period starting September 5, 2023, leading to multiple review cycles. The NOFO emphasizes the importance of innovation in imaging capabilities tailored to end-user needs, setting the stage for advancements in clinical and non-clinical cancer research. The successful applicants will contribute to the development of enhanced imaging tools that improve cancer detection and treatment outcomes, addressing unmet needs in the current healthcare environment.
    Similar Opportunities
    Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)." This initiative aims to support innovative research projects that integrate advanced imaging techniques, biomarkers, and digital pathomics to enhance the early detection of aggressive cancers and precancerous lesions, thereby improving diagnostic accuracy and reducing overdiagnosis. The program emphasizes the importance of multidisciplinary collaboration in cancer research, particularly focusing on high-risk cancers such as pancreatic and lung cancers. Interested applicants, including higher education institutions, nonprofits, and government entities, must submit their proposals by September 7, 2025, and can find additional information and application details at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" funding opportunity (FOA PAR-21-166). This initiative aims to foster collaborations between academic institutions and industry to translate scientific discoveries into practical diagnostic and therapeutic solutions, specifically targeting the development of methods or tools for disease prevention, diagnosis, and treatment. The program is particularly significant as it seeks to bridge gaps in healthcare technology and enhance the effectiveness of disease management across various settings, while explicitly excluding clinical trials. Eligible applicants can receive funding up to $499,000 per year for a maximum of five years, with applications due by January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" initiative, which is part of the Innovative Molecular Analysis Technologies (IMAT) Program. This funding opportunity aims to support exploratory research projects that address significant gaps in current cancer research methodologies, focusing on the development and validation of novel technologies that enhance the understanding and treatment of cancer, including early detection, screening, and addressing health disparities. Eligible applicants can request up to $300,000 annually for a project period not exceeding three years, with a total of approximately $4.3 million available for 10 anticipated awards in fiscal year 2025. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment" (R01 - Clinical Trial Optional), aimed at fostering collaborations between academic and industrial organizations to develop innovative healthcare solutions. This initiative seeks to stimulate the translation of scientific discoveries into practical tools and methods for diagnosing and treating diseases, with a focus on interdisciplinary teamwork and addressing significant health challenges, particularly in low-resource settings. Eligible applicants can request funding up to $499,000 annually for a maximum project duration of five years, with the application deadline set for January 8, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance molecular and cellular analysis capabilities in cancer research, with an emphasis on technical innovation and addressing cancer health disparities. The total funding available is approximately $4.2 million, with individual grants of up to $150,000 per year for a maximum of three years. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at incorporating novel technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program to accelerate cancer research. This initiative encourages currently funded NCI P50 specialized centers to expand upon their original research questions by integrating innovative tools and methods, thereby promoting interdisciplinary collaboration and enhancing the rigor of ongoing studies. With a funding ceiling of $150,000 per year and a total of approximately $600,000 anticipated to support three awards for fiscal year 2025, eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and foreign entities. Interested parties should submit their applications by October 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research," aimed at advancing innovative research in biomimetic tissue-engineered technologies for cancer. This initiative seeks to support collaborative, multidisciplinary projects that integrate regenerative medicine, tissue engineering, and cancer biology to develop advanced in vitro and ex vivo models that accurately mimic human cancer pathophysiology. The funding opportunity is crucial for enhancing cancer research methodologies and understanding disease mechanisms, with a maximum budget of $400,000 per year and a project duration of up to five years. Interested applicants must submit their proposals electronically via Grants.gov by May 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Network Radiotherapy and Imaging Core Services Centers (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a funding opportunity announcement for a cooperative agreement aimed at establishing a Network Radiotherapy and Imaging Core Services Center under the NCI National Clinical Trials Network (NCTN). This center will provide essential scientific and technical expertise for quality control, assurance, and image data management in NCTN trials that involve radiotherapy and imaging modalities, as well as support for other NCI-supported clinical trial programs. The funding opportunity is significant for enhancing cancer treatment research and is expected to have a total program funding of $8.8 million, with a ceiling of $8.14 million for the award. Interested private institutions of higher education should prepare their applications, as the anticipated application due date is in late February 2025, with an estimated award date set for March 1, 2026.
    National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "National Centers for Biomedical Imaging and Bioengineering (NCBIB)" aimed at supporting the development and dissemination of new biomedical technologies. This initiative encourages applications from a diverse range of eligible entities, including higher education institutions and nonprofit organizations, to conduct technology research and development projects, collaborative projects, and service projects that address biomedical challenges. The program is designed to foster innovative research and enhance clinical applications, with funding typically ranging from $600,000 to $750,000 per project, and awards may last up to five years, with a total funding cap of fifteen years for any Center. Interested applicants should note that the application process opens on September 25, 2023, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-235.html.